US10905694B2 - Pharmaceutical solid preparation comprising benzazepines and production method thereof - Google Patents

Pharmaceutical solid preparation comprising benzazepines and production method thereof Download PDF

Info

Publication number
US10905694B2
US10905694B2 US12/665,642 US66564208A US10905694B2 US 10905694 B2 US10905694 B2 US 10905694B2 US 66564208 A US66564208 A US 66564208A US 10905694 B2 US10905694 B2 US 10905694B2
Authority
US
United States
Prior art keywords
solid preparation
hydroxypropylcellulose
content
benzoazepine
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/665,642
Other languages
English (en)
Other versions
US20100323006A1 (en
Inventor
Shinsuke Nakagawa
Kai Suzuki
Tadashi Mukai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
US case filed in Delaware District Court litigation Critical https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A22-cv-00513 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
First worldwide family litigation filed litigation https://patents.darts-ip.com/?family=40070798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US10905694(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Court of Appeals for the Federal Circuit litigation https://portal.unifiedpatents.com/litigation/Court%20of%20Appeals%20for%20the%20Federal%20Circuit/case/24-2297 Source: Court of Appeals for the Federal Circuit Jurisdiction: Court of Appeals for the Federal Circuit "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A21-cv-00900 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A22-cv-00316 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A24-cv-00740 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Assigned to OTSUKA PHARMACEUTICAL CO., LTD. reassignment OTSUKA PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUKAI, TADASHI, NAKAGAWA, SHINSUKE, SUZUKI, KAI
Publication of US20100323006A1 publication Critical patent/US20100323006A1/en
Application granted granted Critical
Publication of US10905694B2 publication Critical patent/US10905694B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the present invention relates to a pharmaceutical solid preparation and a production method thereof.
  • Japanese Unexamined Patent Publication No. 1999-21241 teaches a technique to improve the solubility of benzoazepine compound by combining a benzoazepine compound with a hydroxypropylcellulose, forming an amorphous composite.
  • This technique improves the solubility of the benzoazepine compound; however, when the amorphous composite containing the benzoazepine compound is compressed directly into a tablet, the tablet does not disintegrate at all in the gastrointestinal tract. For this reason, the medicine exhibits no pharmacological activity.
  • the amorphous composite thus varies in disintegration properties, particularly in tablet form, and greatly varies in disintegration rate. This results in inconsistent pharmacological activity, and it is not possible to obtain medicinal products of consistent pharmacological activity.
  • An object of the present invention is to provide a novel pharmaceutical solid preparation with superior disintegration properties and excellent solubility and absorbability of active ingredients in the gastrointestinal tract.
  • the present invention also provides a production method for the pharmaceutical solid preparation.
  • amorphous composite obtained by a benzoazepine compound and hydroxypropylcellulose, with a specific low substituted hydroxypropylcellulose, produces a pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients in the gastrointestinal tract.
  • the inventors also found that mixing the amorphous composite, obtained by a benzoazepine compound and hydroxypropylcellulose, either with carmellose, sodium carboxy methyl starch or crospovidone, produces a similar pharmaceutical solid preparation.
  • the present invention is made in view of such findings, and provides a pharmaceutical solid preparation and a production method thereof, as defined in the following Items 1 to 30.
  • Item 1 A pharmaceutical solid preparation comprising:
  • Step 2 of mixing the amorphous composite obtained in Step 1 with low substituted hydroxypropylcellulose, an average particle diameter of 30 to 70 ⁇ m, and a 90% cumulative particle diameter of 100 to 200 ⁇ m;
  • Step 3 of processing the mixture obtained in Step 2 into a solid preparation Step 3 of processing the mixture obtained in Step 2 into a solid preparation.
  • Item 7 The pharmaceutical solid preparation according to Item 6, produced by a method further comprising, between Step 1 and Step 2, the step of processing the amorphous composite obtained in Step 1 into granules using a granulation method.
  • Item 8 The pharmaceutical solid preparation according to Item 6, produced by a method further comprising, between Step 2 and Step 3, the step of processing the mixture obtained in Step 2 into granules using a granulation method.
  • Item 9 A method for producing the pharmaceutical solid preparation according to Item 2, the method comprising:
  • Step 2 of mixing the amorphous composite obtained in Step 1 with low substituted hydroxypropylcellulose, an average particle diameter of 30 to 70 ⁇ m, and a 90% cumulative particle diameter of 100 to 200 ⁇ m;
  • Step 3 of processing the mixture obtained in Step 2 into a solid preparation Step 3 of processing the mixture obtained in Step 2 into a solid preparation.
  • Item 10 The method according to Item 9, wherein Step 3 is carried out by processing the mixture obtained in Step 2 into tablets.
  • Item 11 The method according to Item 9 or 10, further comprising, between Step 1 and Step 2, the step of processing the amorphous composite obtained in Step 1 into granules using a granulation method.
  • Item 12 The method according to Item 9 or 10, further comprising, between Step 2 and Step 3, the step of processing the mixture obtained in Step 2 into granules using a granulation method.
  • a pharmaceutical solid preparation comprising:
  • Step 2 of mixing the amorphous composite obtained in Step 1 with carmellose;
  • Step 3 of processing the mixture obtained in Step 2 into a solid preparation Step 3 of processing the mixture obtained in Step 2 into a solid preparation.
  • Item 16 The method according to Item 15, wherein Step 3 is carried out by processing the mixture obtained in Step 2 into tablets.
  • Item 17 The method according to Item 15 or 16, further comprising, between Step 1 and Step 2, the step of processing the amorphous composite obtained in Step 1 into granules using a granulation method.
  • Item 18 The method according to Item 15 or 16, further comprising, between Step 2 and Step 3, the step of processing the mixture obtained in Step 2 into granules using a granulation method.
  • a pharmaceutical solid preparation comprising:
  • Step 2 of mixing the amorphous composite obtained in Step 1 with sodium carboxy methyl starch;
  • Step 3 of processing the mixture obtained in Step 2 into a solid preparation Step 3 of processing the mixture obtained in Step 2 into a solid preparation.
  • Item 22 The method according to Item 21, wherein Step 3 is carried out by processing the mixture obtained in Step 2 into tablets.
  • Item 23 The method according to Item 21 or 22, further comprising, between Step 1 and Step 2, the step of processing the amorphous composite obtained in Step 1 into granules using a granulation method.
  • Item 24 The method according to Item 21 or 22, further comprising, between Step 2 and Step 3, the step of processing the mixture obtained in Step 2 into granules using a granulation method.
  • Item 25 A pharmaceutical solid preparation comprising:
  • Step 2 of mixing the amorphous composite obtained in Step 1 with crospovidone;
  • Step 3 of processing the mixture obtained in Step 2 into a solid preparation Step 3 of processing the mixture obtained in Step 2 into a solid preparation.
  • Item 28 The method according to Item 27, wherein Step 3 is carried out by processing the mixture obtained in Step 2 into tablets.
  • Item 29 The method according to Item 27 or 28, further comprising, between Step 1 and Step 2, the step of processing the amorphous composite obtained in Step 1 into granules using a granulation method.
  • Item 30 The method according to Item 27 or 28, further comprising, between Step 2 and Step 3, the step of processing the mixture obtained in Step 2 into granules using a granulation method.
  • a pharmaceutical solid preparation according to the present invention comprises:
  • Solid Preparation A a solid preparation containing, as the component (c) low substituted hydroxypropylcellulose, an average particle diameter of 30 to 70 ⁇ m, and a 90% cumulative particle diameter of 100 to 200 ⁇ m is referred to as a Solid Preparation A; a solid preparation containing carmellose as the essential ingredient of component (c) is referred to as Solid Preparation B; a solid preparation containing sodium carboxy methyl starch as the essential ingredient of component (c) is referred to as Solid Preparation C; and a solid preparation containing crospovidone as the essential ingredient of Component (c) is referred to as Solid Preparation D.
  • Solid Preparation A of the present invention comprises:
  • the benzoazepine compound is 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or a salt thereof represented by the following General Formula (1).
  • the salt of benzoazepine designates, for example, salt obtained by mixing an acid or a basic compound pharmacologically compatible with the benzoazepine represented by General Formula (1).
  • Examples of the basic compound which forms salt with benzoazepine include metal hydroxides such as sodium hydroxides, potassium hydroxides, lithium hydroxides, calcium hydroxides; alkali metal carbonates such as sodium carbonates; alkali metal bicarbonates such as sodium hydrogen carbonates; and alkali metal alcoholates such as sodium methylates or potassium ethylates.
  • metal hydroxides such as sodium hydroxides, potassium hydroxides, lithium hydroxides, calcium hydroxides
  • alkali metal carbonates such as sodium carbonates
  • alkali metal bicarbonates such as sodium hydrogen carbonates
  • alkali metal alcoholates such as sodium methylates or potassium ethylates.
  • Examples of the acid which forms salt with benzoazepine include inorganic acids such as sulfuric acid, nitric acid, hydrochloric acid, or hydrobromic acid; and organic acids such as acetic acid, p-toluene sulfonic acid, ethane sulfonic acid, oxalic acid, maleic acid, fumaric acid, citric acid, succinic acid, or benzoic acid.
  • inorganic acids such as sulfuric acid, nitric acid, hydrochloric acid, or hydrobromic acid
  • organic acids such as acetic acid, p-toluene sulfonic acid, ethane sulfonic acid, oxalic acid, maleic acid, fumaric acid, citric acid, succinic acid, or benzoic acid.
  • benzoazepine compound examples include solvates of benzoazepine such as hydrates and ethanolates.
  • the Component (a) as the benzoazepine compound may be selected from various crystal polymorphisms. Additionally, there are various stereoisomers and opticalisomers of the benzoazepine compound of the present invention. It is also possible to use them as Component (a).
  • the benzoazepine compound of the present invention comprises at least one member selected from the group consisting of 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and salt thereof.
  • the benzoazepine compound of the present invention may be produced with any publicly known method, for example, the method disclosed in Japanese Unexamined Patent Publication No. 1992-154765 or No. 1999-21241.
  • Component (b) is water-soluble cellulose ether containing a hydroxyl propyl group in an amount of about 50% or greater, preferably in a range from about 53 to 80 wt. %.
  • Component (b) is a compound having a repeating unit represented by the following General Formula (2).
  • R 1 , R 2 and R 3 each represents a hydrogen atom or a group:
  • the hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater can be any compound represented by the foregoing Formula (2).
  • the viscosity of the aqueous solution is preferably 2 to 10 cps, and more preferably 3 to 6 cps at 20° C.
  • the hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater used for the present invention can be produced by a publicly known method, or may be selected from commercially available products.
  • Examples of the marketed commodity of the hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater include “HPC-L”, “HPC-SL”, and “HPC-SSL” (Nippon Soda Co. Ltd.), and “Klucel EF” (Hercules).
  • the low substituted hydroxypropylcellulose is cellulose containing a hydroxy propoxyl group in an amount of about 5 to 16 wt. %, preferably in an amount of about 10 to 13 wt. %.
  • the average particle diameter of the low substituted hydroxypropylcellulose approximately ranges from 30 to 70 ⁇ m, preferably from 45 to 65 ⁇ m.
  • the 90% cumulative particle diameter of the low substituted hydroxypropylcellulose is generally around 100 to 200 ⁇ m, and preferably ranges from 150 to 200 ⁇ m.
  • the average particle diameter and 90% cumulative particle diameter falling within the foregoing range secure the disintegration properties of the solid preparation.
  • the content of the low substituted hydroxypropylcellulose can be measured by a method according to Japanese Pharmacopoeia, for example.
  • the particle distribution and the average particle diameter of the low substituted hydroxypropylcellulose may be measured by a dry method using a laser diffraction type particle size distribution analyzer. The resulting value is used to find the 90% cumulative particle diameter.
  • the low substituted hydroxypropylcellulose preferably has a small water-soluble content in terms of security for the disintegration property.
  • the water soluble content is preferably about 3% or less.
  • the low substituted hydroxypropylcellulose used for the present invention can be produced by a publicly known method, or may be selected from commercially available products.
  • Examples of the marketed commodity of low substituted hydroxypropylcellulose include “LH-11”, “LH-21”, and “LH-B1” (Shin-Etsu Chemical Co., Ltd.).
  • the (c-1) low substituted hydroxypropylcellulose may be used with other disintegrating agents, insofar as the effects of the present invention are not impaired.
  • plural kinds of disintegrating agents may be used with the hydroxypropylcellulose.
  • the (c-1) low substituted hydroxypropylcellulose is used not only as a disintegrating agent, but also as other kinds of agents, such as binders, diluents, or other additives.
  • the (c-1) low substituted hydroxypropylcellulose is preferable because it is compatible with the drug and also easy to handle.
  • the content of the (a) benzoazepine compound in Solid Preparation A is not particularly limited, and may range widely.
  • the content is generally about 0.01 to 95 wt. %, preferably about 0.05 to 65 wt. %, and more preferably about 0.1 to 50%.
  • the content of the (b) hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater is generally about 0.01 to 2 times, preferably about 0.1 to 1.5 times, and particularly preferably about 0.2 to 1 times the (a) benzoazepine compound in weight.
  • the content of the (c-1) low substituted hydroxypropylcellulose in Solid Preparation A is generally about 1 to 15 wt. %, preferably about 2 to 13 wt. %, and more preferably about 3 to 12 wt. %. This content range ensures desirable disintegration properties.
  • Solid Preparation A of the present invention may contain other regular ingredients for pharmaceutical solid preparations, such as diluents, binders, pH adjusters, absorption enhancers, lubricants, coloring agents, corrective substances, or perfumes.
  • diluents such as diluents, binders, pH adjusters, absorption enhancers, lubricants, coloring agents, corrective substances, or perfumes.
  • binders such as binders, pH adjusters, absorption enhancers, lubricants, coloring agents, corrective substances, or perfumes.
  • Solid Preparation A may be a form of powder, granule, tablet, pill, capsule etc.
  • the present invention prefers the form of a powder, granule, capsules, or tablet in view of the benefits of easy dosages.
  • the tablet form is particularly preferable.
  • a production method for Solid Preparation A of the present invention comprises the following Steps 1, 2 and 3.
  • Step 1 producing an amorphous composite from 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl benzoylamino) benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or a salt thereof (benzoazepine compound), and hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater;
  • Step 2 mixing the amorphous composite produced in Step 1 with low substituted hydroxypropylcellulose;
  • Step 3 processing the mixture obtained in Step 2 into a solid preparation.
  • Step 1 is a process for producing an amorphous composite from a benzoazepine compound, and hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater.
  • the amorphous composite can be produced in many ways, including the following.
  • a benzoazepine compound and a hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater are dissolved in an organic solvent, and the organic solvent is then distilled off by a known method to obtain a solid composite (e.g., a powder) of the amorphous composite.
  • the amorphous composite can also be produced using a heat-melt kneading technology; for example, using a two-screw extruder.
  • This method which does not use an organic solvent, has advantages such as low environmental pollution risk and high production efficiency.
  • the amorphous composite can also be produced using an ultrasonic tablet producing machine (rotary tablet machine, compression molding machine, etc.).
  • any conventionally-known organic solvent that can dissolve the hydroxypropylcellulose containing benzoazepine and a hydroxy propoxyl group in an amount of 50% or greater can be used.
  • the organic solvent include lower alcohols such as methanol, ethanol or isopropanol; ketones such as acetone, methyl ethyl ketone; halogenation carbon hydrides such as dichloromethane, dichloroethane, chloroform, or carbon tetrachloride; and mixed solvents of those.
  • a mixed solvent of lower alcohol and halogenation carbon hydride are particularly preferable in terms of solubility, distillation, etc.
  • a mixed solvent of dichloromethane, and methanol and/or ethanol is particularly preferable.
  • the lower alcohol and the halogenation carbon hydride are mixed at a weight ratio of about 99:1 to 1:99.
  • the methanol and/or ethanol and the dichloromethane are mixed at a weight ratio of about 99:1 to 1:99, preferably 10:90 to 40:60. 0.01 to 5 wt. % of water may be added to the organic solvent.
  • the organic solvent can be distilled off by an evaporation method, spray drying method, fluidized bed drying method or the like.
  • a spray drying method is preferable.
  • the shape of the amorphous composite of the present invention is not particularly limited.
  • the amorphous composite may be in the form of a powder, or a round or square solid of a certain size.
  • Step 2 is a process for mixing the amorphous composite produced from Component (a) and Component (b) in Step 1 with (c-1) low substituted hydroxypropylcellulose.
  • the mixing method is not particularly limited.
  • a diffusion blender a container rotating type
  • a convection mixer a machine stirring type
  • a kneader a kneader
  • an airflow type mixer or the like can be used.
  • a lubricant may be added. Adding a lubricant gives some effects, including suppression of impediments in the following Step 3 of processing the solid preparation into tablets.
  • lubricants include powdered gum arabic, carnauba wax, carmellose calcium, carmellose sodium, hydrated silicon dioxide, dried aluminum hydroxide gel, grycerol esters of fatty acid, magnesium silicate, light anhydrous silicic acid, crystalline cellulose, hydrogenated oil, synthetic aluminum silicate, magnesium oxide, wheat starch, white beeswax, heavy anhydrous silicic acid, sucrose esters of fatty acid, stearyl alcohol, stearic acid, aluminum stearate, calcium stearate, polyoxyl 40 stearate, magnesium stearate, cetanol, gelatin, talc, magnesium carbonate, precipitated calcium carbonate, corn starch, lactose, sucrose, hard fat, potato starch, fumaric acid, sodium stearyl fumarate, polyoxyethylene (160), polyoxypropylene (30) glycol, polysorbate 80, macrogol 400, macrogol 600, macrogol 1500, macrogol 4000, macrogol 6000, yellow beesw
  • the production method of the present invention preferably comprises, between Step 1 and Step 2, Step 1′ of processing the amorphous composite into granules using a granulation method, or, between Step 2 and Step 3, Step 2′ of processing the mixture resulting from Step 2 into granules using a granulation method.
  • Step 1′ it is preferable to use a diluent and a binder.
  • Examples of the diluent used in the granulation method include L-aspartic acid, maltose syrup powder, acacia, powdered acacia, alginic acid, sodium alginate, pregelatinized starch, inositol, ethylcellulose, ethylene and vinyl acetate copolymer, erythritol, sodium chloride, kaolin, casein, sodium caseinate, fructose, sodium carboxy methyl starch, carmellose, carmellose calcium, carmellose sodium, hydrated silicon dioxide, amorphous silicon oxide hydrate, agar, powdered agar, xylitol, citric acid, glycine, glycerol esters of fatty acid, crosscarmellose sodium, crospovidone, magnesium aluminosilicate, calcium silicate, magnesium silicate, light anhydrous silicic acid, crystalline cellulose, crystalline cellulose and carmellose sodium, hydrogenated oil, wheat starch, potassium
  • binder examples include ethyl acrylate and methyl methacrylate copolymer dispersion, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate copolymer RS, amylopectin, maltose syrup powder, acacia, powdered acacia, sodium alginate, pregelatinized starch, ethylcellulose, powdered hydrolyzed gelatin, sodium caseinate, fructose, carboxy vinyl polymer, carboxymethyl ethylcellulose, sodium carboxymethyl starch, carmellose, carmellose sodium, hydrated silicon dioxide, agar, hydrogenated tallow, powdered agar, guar Gum, glycerin, light anhydrous silicic acid, crystalline cellulose, hydrogenated oil, synthetic aluminum silicate, poly [(2-oxo-1pyrrolidinyl) ethylene], copolyvidone, rice powder, wheat starch, polyvinyl acetate, cellulose acetate
  • Step 1′ after Step 1, or Step 2′ after Step 2
  • filling a solid preparation into dies of tabletting machine is improved because the solid preparation is densified in a granulation process.
  • the granulation method in Step 1′ or 2′ is not particularly limited, and any granulation method may be used according to, for example, the target dosage forms. Examples of the granulation methods include dry granulation methods and wet granulation methods (e.g., a fluidized-bed granulation method, a kneading granulation method, etc.).
  • Step 3 is a step for processing the mixture obtained in Step 2 into a solid preparation.
  • the method for processing the mixture into a solid preparation depends on the target dosage forms.
  • the target dosage form of a solid preparation is tablets
  • the mixture may be compressed with a tabletting machine.
  • tabletting methods include dry tabletting method, a wet tabletting method, and an external lubrication tabletting method, etc.
  • Solid preparation may be film-coated to mask the drug related taste, or to improve the photostability.
  • Solid Preparation A may be coated with an enteric film or a sustained-release film to modify a drug release in the gastrointestinal tract.
  • Solid Preparation B of the present invention contains:
  • Solid Preparation B uses the same benzoazepine compound as Solid Preparation A.
  • the hydroxypropylcellulose used for Solid Preparation B is the same hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater used for Solid Preparation A.
  • Carmellose can be produced with one of the publicly known methods. Additionally, commercial items such as the “NS-300”, produced by Nichirin Chemical Co., are readily available.
  • Solid Preparation B may contain other disintegrating agents together with the (c-2) carmellose within a range not to impair the effect of the present invention.
  • disintegrating agents may be used.
  • the (c-2) carmellose is used not only as a disintegrating agent, but also as a binder, a diluent, or other additive.
  • the content of the (a) benzoazepine compound in the solid formulation B is not particularly limited and can vary widely, but is generally about 0.01 to 95 wt. %, preferably about 0.05 to 65 wt. %, and more preferably 0.1 to 50%.
  • the proportion of the (b) hydroxypropylcellulose containing at least 50% hydroxy propoxyl group is generally 0.01 to 2 times, preferably 0.1 to 1.5 times, and particularly preferably 0.2 to 1 times the (a) benzoazepine compound.
  • the content of the (c-2) carmellose in Solid Preparation B is generally 7 to 15 wt. %, preferably 9 to 13 wt. %, and more preferably 10 to 12 wt. %.
  • the content in this range ensures a desirable disintegration property.
  • each of the (a) benzoazepine compound and the (b) hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater is a form of amorphous composite.
  • Solid Preparation B may contain other ingredients for use in pharmaceutical solid preparations, in addition to the Components (a), (b) and (c-2).
  • ingredients include diluents, binders, pH adjusters, absorption enhancers, lubricants, colorant flavoring agents, or perfumes.
  • Solid Preparation B containing (a) benzoazepine compound, the (b) hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater, and the (c-2) carmellose may be a form of powder, granule, tablet, pill, or capsule.
  • the present invention prefers the form of a powder, granule, capsules, and tablet in view of easy preparation and dose.
  • the tablet form is particularly preferable.
  • Solid Preparation B is prepared in the same manner as Solid Preparation A, except that carmellose is used instead of the low substituted hydroxypropylcellulose.
  • Solid Preparation C of the present invention comprises:
  • Solid Preparation C uses the same benzoazepine compound as Solid Preparation A.
  • the hydroxypropylcellulose used for Solid Preparation C is the same as the hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater used for Solid Preparation A.
  • Sodium carboxy methyl starch can be obtained easily from commercial items, for example, “GLYCOLYS LV” (Roquette), and “Primojel” (DMV). Partly pregelatinized starch may also be used as Component (c-3).
  • the partly pregelatinized starch can be obtained easily from commercial items, for example, “PCS” (Asahi Kasei Chemicals), “Starch 1500” (Colorcon), or “LYCATAB C” (Roquette).
  • the average particle diameter of the sodium carboxy methyl starch is, for example, not more than 105 ⁇ m, preferably not more than 80 ⁇ m, and more preferably about 20 to 65 ⁇ m.
  • the average particle diameter of the partly pregelatinized starch is, for example, not more than 150 ⁇ m, preferably not more than 100 ⁇ m, and more preferably about 15 to 85 ⁇ m.
  • the water soluble content of the partly pregelatinized starch is generally about not more than 20 wt. %, preferably about not more than 10 wt. %, and further preferably about 1 to 4 wt. %, with respect to room-temperature water.
  • metal-free partly pregelatinized starch or the like also exhibits a relatively desirable disintegration property when used in a small amount as the disintegrating agent in the solid preparation.
  • the metal-free partly pregelatinized starch can therefore be useful for the solid preparation of the present invention when the content of the disintegrating agent is small.
  • metal-containing sodium carboxy methyl starch becomes more suitable than metal-free partly pregelatinized starch, in terms of disintegration properties.
  • a metal-free substance is more suitable than a metal-containing substance, in terms of disintegration properties, regardless of its content.
  • Solid Preparation C may contain other disintegrating agents together with the (c-3) sodium carboxy methyl starch within a range not to impair the effect of the present invention.
  • disintegrating agents may be used.
  • the (c-3) sodium carboxy methyl starch is used not only as a disintegrating agent, but also as a binder, a diluent, or another additive.
  • the content of the (a) benzoazepine compound in the solid formulation B is not particularly limited and can vary widely, but is generally about 0.01 to 95 wt. %, preferably about 0.05 to 65 wt. %, and more preferably 0.1 to 50%.
  • the proportion of the (b) hydroxypropylcellulose containing at least 50% hydroxy propoxyl group is generally about 0.01 to 2 times, preferably about 0.1 to 1.5 times, and particularly preferably about 0.2 to 1 times the (a) benzoazepine compound.
  • the content of the (c-3) sodium carboxy methyl starch in Solid Preparation C is generally about 0.5 to 15 wt. %, preferably about 1 to 10 wt. %, and more preferably about 1 to 5 wt. %. The content in this range ensures desirable disintegration properties.
  • the content is not particularly limited; however, the content is generally about 1 to 15 wt. %, preferably about 2 to 10 wt. %, and more preferably about 3 to 7 wt. %, based on the whole quantity of the solid preparation.
  • Solid Preparation C may contain other ingredients for use in pharmaceutical solid preparations in addition to the Components (a), (b) and (c-3).
  • ingredients include diluents, binders, pH adjusters, absorption enhancers, lubricants, colorant flavoring agents or perfumes.
  • Solid Preparation C containing (a) benzoazepine compound, the (b) hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater, and the (c-3) sodium carboxy methyl starch may be in the form of a powder, granule, tablet, pill, or capsule.
  • the present invention prefers powders, granules, capsules, and tablets, in view of easy preparation and dose. Tablets are particularly preferable.
  • Solid Preparation C is prepared in the same manner as Solid Preparation A, except that sodium carboxy methyl starch is used instead of low substituted hydroxypropylcellulose.
  • Solid Preparation D according to the present invention comprises:
  • the benzoazepine compound used for Solid Preparation D is the same as the benzoazepine compound used for Solid Preparation A.
  • the hydroxypropylcellulose used for Solid Preparation D is the same as the hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater used for Solid
  • Crospovidon designates a synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidinone, not soluble in water.
  • the content of the (a) benzoazepine compound in Solid Preparation D is not particularly limited and can vary widely, but is generally about 0.01 to 95 wt. %, preferably about 0.05 to 65 wt. %, and more preferably 0.1 to 50 wt. %.
  • the proportion of the (b) hydroxypropylcellulose containing at least 50% hydroxy propoxyl group is generally about 0.01 to 2 times, preferably about 0.1 to 1.5 times, and particularly preferably about 0.2 to 1 times the (a) benzoazepine compound.
  • the content of the (c-4) crospovidone in Solid Preparation D is generally about 2 to 15 wt. %, preferably about 3 to 12 wt. %, and more preferably about 3 to 10 wt. %. The content in this range ensures desirable disintegration properties.
  • Solid Preparation D may contain other disintegrating agent for use in pharmaceutical solid preparations, in addition to the (c-4) crospovidone.
  • disintegrating agent for use in pharmaceutical solid preparations, in addition to the (c-4) crospovidone.
  • plural kinds of disintegrating agents may be used.
  • the (c-4) crospovidone is used not only as a disintegrating agent but also as a binder, a diluent, or another additive.
  • Solid Preparation D may contain other ingredients for use in pharmaceutical solid preparations, in addition to the Components (a), (b) and (c-4).
  • the ingredients include diluents, binders, pH adjusters, absorption enhancers, lubricants, colorant flavoring agents, or perfumes. The contents of these additional ingredients fall within the range not to impair the effect of the present invention.
  • Solid Preparation D containing (a) benzoazepine compound, the (b) hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater, and the (c-4) crospovidone may be in the form of a powder, granules, tablet, pill, or capsule.
  • the present invention prefers the form of a powder, granules, capsules, or tablet in view of easy preparation and dose. Tablets are particularly preferable.
  • Solid Preparation D is prepared in the same manner as Solid Preparation A, except that crospovidone is used instead of low substituted hydroxypropylcellulose.
  • Each unit of Solid Preparations A to D of the present invention in the dosage form preferably contains the (a) benzoazepine compound as an active ingredient in an amount of about 0.1 to 120 mg, preferably about 1 to 90 mg, and more preferably about 5 to 60 mg.
  • the doses of Solid Preparations A to D are determined depending on the usage, the patient's condition including age and sex, the degree of disease, etc. Generally, the amount of the (a) benzoazepine compound as an active ingredient per day is about 0.02 to 2 mg per kg of the patient's weight.
  • composition of the present invention shows superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients in the gastrointestinal tract.
  • Solid Preparation A according to the present invention ensures far superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients in the gastrointestinal tract.
  • Solid Preparation A of the present invention ensures uniform disintegration properties of the products, thereby reducing variation in disintegration time among the products. Consequently, Solid Preparation A is expected to exhibit the best invariable pharmacological effect and is thereby the most preferable.
  • the method according to the present invention produces a pharmaceutical solid preparation with these advantageous characteristics.
  • the content of LH-11 in the flat tablet was 1.2 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 1.4 g of LH-11, and 0.3 g of magnesium stearate were mixed.
  • the content of LH-11 in the flat tablet was 5.2 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 2.9 g of LH-11, and 0.4 g of magnesium stearate were mixed.
  • the content of LH-11 in the flat tablet was 10.3 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 4.4 g of LH-11, and 0.3 g of magnesium stearate were mixed.
  • the content of LH-11 in the flat tablet was 14.9 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.5 g of LH-21, and 0.1 g of magnesium stearate were mixed. A flat tablet about 87 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of LH-21 in the flat tablet was 5.2 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.5 g of LH-B1, and 0.1 g of magnesium stearate were mixed. A flat tablet about 87 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner of Example 1.
  • the content of LH-B1 in the flat tablet was 5.2 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, and 0.3 g of magnesium stearate were mixed.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.1 g of LH-31, and 0.1 g of magnesium stearate were mixed. A flat tablet about 84 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of LH-31 in the flat tablet was 1.2 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.5 g of LH-31, and 0.1 g of magnesium stearate were mixed. A flat tablet about 87 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of LH-31 in the flat tablet was 5.2 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.3 g of Ac-Di-Sol, and 0.3 g of magnesium stearate were mixed.
  • the content of Ac-Di-Sol in the flat tablet was 1.2 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 1.3 g of Ac-Di-Sol, and 0.3 g of magnesium stearate were mixed. A flat tablet about 87 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of Ac-Di-Sol in the flat tablet was 5.2 wt. %.
  • the content of Ac-Di-Sol in the flat tablet was 10.3 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 4.4 g of Ac-Di-Sol, and 0.3 g of magnesium stearate were mixed.
  • the content of Ac-Di-Sol in the flat tablet was 14.9 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.3 g of ECG-505, and 0.3 g of magnesium stearate were mixed.
  • the content of ECG-505 in the flat tablet was 1.2 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 1.4 g of ECG-505, and 0.3 g of magnesium stearate were mixed.
  • the content of ECG-505 in the flat tablet was 5.2 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 2.9 g of ECG-505, and 0.3 g of magnesium stearate were mixed.
  • the content of ECG-505 in the flat tablet was 10.3 wt. %.
  • Example 2 24.5 g of the granulation substance prepared in the above-mentioned Reference Example 2, 4.4 g of ECG-505, and 0.3 g of magnesium stearate are mixed.
  • the content of ECG-505 in the flat tablet was 14.9 wt. %.
  • Table 1 shows the results of the disintegration test for Examples 1 to 6 and Comparative Examples 1 to 11.
  • Example 1 70.8 ⁇ 5.8 (LH-11, 1.2%)
  • Example 2 63.7 ⁇ 3.9 (LH-11, 5.2%)
  • Example 3 52.8 ⁇ 2.4 (LH-11, 10.3%)
  • Example 4 60.5 ⁇ 2.0 (LH-11, 14.9%)
  • Example 6 75.5 ⁇ 1.9 (LH-B1, 5.2%)
  • Comparative Example 1 95.8 ⁇ 6.1 (No Disintegrating Agent) Comparative Example 2 104.7 ⁇ 6.2 (LH-31, 1.2%) Comparative Example 3 130.3 ⁇ 37.4 (LH-31, 5.2%) Comparative Example 4 92.3 ⁇ 3.0 (Ac-Di-Sol, 1.2%) Comparative Example 5 161.3 ⁇ 12.0 (Ac-Di-Sol, 5.2%) Comparative Example 6 163.8 ⁇ 3.5 (Ac-Di-Sol, 10.3%) Comparative Example 7 188.0 ⁇ 3.8
  • Example 5 which uses LH-21 as a disintegrating agent, the disintegration time was shorter than Comparative Example 1 not containing any disintegrating agent, and desirable disintegration properties were obtained.
  • Example 6 which uses LH-B1 as disintegrating agent, the disintegration time was shorter than Comparative Example 1 not containing any disintegrating agents. Desirable disintegration properties were thus obtained.
  • Table 2 shows the average value and variation in disintegration time among the six solid samples (No. 1 to 6) for each of Examples 2, 5, and 6 and Comparative Example 3, which were measured in the above-mentioned Experiment Example 1.
  • Example 5 Example 6
  • Example 3 Disinte- 1 58 70 73 106 gration 2 60 72 74 107 Time 3 64 73 75 112 (Seconds) 4 66 80 76 121 5 66 86 77 132 6 68 98 78 204 Average Disintegration 63.7 79.8 75.5 130.3 Time (Seconds) Variation (Seconds) 3.9 10.7 1.9 37.4
  • the variation in disintegration time in Example 2 using LH-11 as a disintegrating agent was 3.9 seconds; the variation in disintegration time in Example 5 using LH-21 was 10.7 seconds; and the variation in disintegration time in Example 6 using LH-B1 was 1.9 seconds. That is, the variation in disintegration time was small for the tablets of all Examples 2, 5, and 6; more specifically, the tablets of these Examples ensure a uniform pharmacologic effect.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.5 g of NS-300, and 0.1 g of magnesium stearate were mixed. A flat tablet about 87 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of NS-300 in the flat tablet was 5.2 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 1.0 g of NS-300, and 0.1 g of magnesium stearate were mixed. A flat tablet about 92 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of NS-300 in the flat tablet was 10.3 wt. %.
  • test fluid water, no disk
  • Table 3 shows the results of the disintegration test for Examples 7 and 8.
  • Example 8 using 10.3 wt. % of NS-300 in each table was significantly shorter than that of Comparative Examples 1 to 11. The disintegration properties of Example 8 were thus excellent.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.1 g of Primojel, and 0.1 g of magnesium stearate were mixed. A flat tablet about 84 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of Primojel in the flat tablet was 1.2 wt. %.
  • the content of Primojel in the flat tablet was 5.2 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 1.0 g of Primojel, and 0.1 g of magnesium stearate were mixed. A flat tablet about 92 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of Primojel in the flat tablet was 10.3 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.5 g of PCS PC-10, and 0.1 g of magnesium stearate were mixed. A flat tablet about 87 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of PCS PC-10 in the flat tablet was 5.2 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 1.0 g of PCS PC-10, and 0.1 g of magnesium stearate were mixed. A flat tablet about 92 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of PCS PC-10 in the flat tablet was 10.3 wt. %.
  • a disintegration test was conducted for each of the six solid samples in Examples 9 to 13, using a disintegration test method according to Japanese Pharmacopeia (test fluid: water, no disk).
  • Table 4 shows the results of the disintegration test for Examples 9 to 13.
  • Example 9 58.8 ⁇ 7.4 (Primojel, 1.2%)
  • Example 10 65.2 ⁇ 4.2 (Primojel, 5.2%)
  • Example 11 72.2 ⁇ 7.4 (Primojel, 10.3%)
  • Example 12 87.2 ⁇ 5.3 (PCS PC-10, 5.2%)
  • Example 13 92.5 ⁇ 2.9 (PCS PC-10, 10.3%)
  • Example 9 the disintegration time was significantly short in Example 9 using 1.2 wt. % of Primojel as a disintegrating agent, compared with Comparative Examples 1 to 11.
  • the disintegration properties of Example 9 were thus excellent.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.1 g of Polyplasdone XL, and 0.1 g of magnesium stearate were mixed. A flat tablet about 84 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of Polyplasdone XL in the flat tablet was 1.2 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 0.5 g of Polyplasdone XL, and 0.1 g of magnesium stearate were mixed. A flat tablet about 87 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of Polyplasdone XL in the flat tablet was 5.2 wt. %.
  • Example 2 8.2 g of the granulation substance prepared in the above-mentioned Reference Example 2, 1.0 g of Polyplasdone XL, and 0.1 g of magnesium stearate were mixed. A flat tablet about 92 mg in weight, containing 15 mg of the main ingredient, was produced in the same manner as Example 1.
  • the content of Polyplasdone XL in the flat tablet was 10.3 wt. %.
  • a disintegration test was conducted for each of the six solid samples in Examples 14 to 16, using a disintegration test method according to Japanese Pharmacopeia (test fluid: water, no disk).
  • Table 5 shows the results of the disintegration test for Examples 14 to 16.
  • Example 14 80.5 ⁇ 19.9 (Polyplasdone XL, 1.2%)
  • Example 15 73.5 ⁇ 6.6 (Polyplasdone XL, 5.2%)
  • Example 16 53.8 ⁇ 3.4 (Polyplasdone XL, 10.3%)
  • Example 16 the disintegration time was significantly short in Example 16 using the solid preparation containing 10.3 wt. % of Polyplasdone XL.
  • the disintegration properties of Example 16 were thus excellent.
  • Example 18 With the granules obtained in Example 18, flat tablets were produced with a Rotary Tabletting Machine 12HUK-AWC (product of Kikusui Seisakusho Ltd.), at 40 rpm and under a compression force at 900 kg. Each tablet was about 87 mg in weight, 6 mm in diameter, and contains 15 mg of a main ingredient. The content of LH-11 in each tablet was 5.2 wt. %.
  • the obtained granulation substance was mixed with 27 g of LH-11, and 6 g of magnesium stearate to prepare granules for tablets.
  • flat tablets were produced with a Rotary Tabletting Machine 12HUK-AWC (product of Kikusui Seisakusho Ltd.), at 50 rpm and under a compression force at 1000 kg.
  • Each tablet was about 183 mg in weight, 8 mm in diameter, and contains 7.5 mg of a main ingredient.
  • the content of LH-11 in each tablet was 4.9 wt. %.
  • the pharmaceutical solid preparation of the present invention contains (a) benzoazepine compound, (b) hydroxypropylcellulose containing a hydroxy propoxyl group in an amount of 50% or greater, and a disintegrating agent, which is either (c-1) low substituted hydroxypropylcellulose, (c-2) carmellose, (c-3) sodium carboxy methyl starch or (c-4) crospovidone.
  • a disintegrating agent which is either (c-1) low substituted hydroxypropylcellulose, (c-2) carmellose, (c-3) sodium carboxy methyl starch or (c-4) crospovidone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/665,642 2007-06-21 2008-06-20 Pharmaceutical solid preparation comprising benzazepines and production method thereof Active 2030-04-07 US10905694B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007-163551 2007-06-21
JP2007163551 2007-06-21
PCT/JP2008/061686 WO2008156217A2 (en) 2007-06-21 2008-06-20 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061686 A-371-Of-International WO2008156217A2 (en) 2007-06-21 2008-06-20 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/099,221 Continuation US20210069207A1 (en) 2007-06-21 2020-11-16 Pharmaceutical solid preparation comprising benzazepines and production method thereof
US17/132,852 Continuation US20210113582A1 (en) 2007-06-21 2020-12-23 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Publications (2)

Publication Number Publication Date
US20100323006A1 US20100323006A1 (en) 2010-12-23
US10905694B2 true US10905694B2 (en) 2021-02-02

Family

ID=40070798

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/665,642 Active 2030-04-07 US10905694B2 (en) 2007-06-21 2008-06-20 Pharmaceutical solid preparation comprising benzazepines and production method thereof
US17/099,221 Abandoned US20210069207A1 (en) 2007-06-21 2020-11-16 Pharmaceutical solid preparation comprising benzazepines and production method thereof
US17/132,852 Abandoned US20210113582A1 (en) 2007-06-21 2020-12-23 Pharmaceutical solid preparation comprising benzazepines and production method thereof
US18/336,534 Pending US20230321113A1 (en) 2007-06-21 2023-06-16 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US17/099,221 Abandoned US20210069207A1 (en) 2007-06-21 2020-11-16 Pharmaceutical solid preparation comprising benzazepines and production method thereof
US17/132,852 Abandoned US20210113582A1 (en) 2007-06-21 2020-12-23 Pharmaceutical solid preparation comprising benzazepines and production method thereof
US18/336,534 Pending US20230321113A1 (en) 2007-06-21 2023-06-16 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Country Status (25)

Country Link
US (4) US10905694B2 (he)
EP (1) EP2167046B1 (he)
JP (1) JP5289338B2 (he)
KR (1) KR101526625B1 (he)
CN (3) CN103463095A (he)
AR (1) AR067077A1 (he)
AT (1) ATE489944T1 (he)
AU (1) AU2008264445B2 (he)
BR (1) BRPI0813100A2 (he)
CA (1) CA2689467A1 (he)
CY (1) CY1111939T1 (he)
DE (1) DE602008003816D1 (he)
DK (1) DK2167046T3 (he)
ES (1) ES2354030T3 (he)
HK (1) HK1201719A1 (he)
HR (1) HRP20100676T1 (he)
IL (1) IL202179A (he)
MX (1) MX2009014193A (he)
MY (1) MY147599A (he)
PL (1) PL2167046T3 (he)
PT (1) PT2167046E (he)
RU (1) RU2466717C2 (he)
SI (1) SI2167046T1 (he)
TW (1) TWI405574B (he)
WO (1) WO2008156217A2 (he)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022256378A1 (en) 2021-06-02 2022-12-08 Esperion Therapeutics, Inc. Compositions containing and therapies using bempedoic acid and tolvaptan

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293734A (zh) 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102552278A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种提高难溶性药物托伐普坦溶出度的药物组合物
CN102228423B (zh) * 2011-06-29 2013-03-06 重庆市庆余堂制药有限公司 托伐普坦口服固体药物组合物及其制备方法
JP6057628B2 (ja) * 2012-09-06 2017-01-11 クリーンケミカル株式会社 人工透析装置のプライミング方法
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
JP6761695B2 (ja) 2016-08-16 2020-09-30 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース及び固形製剤
JP6838446B2 (ja) * 2017-03-22 2021-03-03 ニプロ株式会社 トルバプタン製剤およびその製造方法
JP7352175B2 (ja) * 2019-12-25 2023-09-28 ニプロ株式会社 トルバプタン製剤
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
EP4321154A1 (en) 2022-08-03 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet of tolvaptan and at least one binder processed with spray granulation

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2071511A (en) * 1934-10-01 1937-02-23 Reed & Carnrick Enteric coating
JPH04154765A (ja) 1989-10-20 1992-05-27 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
WO1997022340A1 (en) 1995-12-20 1997-06-26 Bristol-Myers Squibb Company Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof
JPH09278656A (ja) 1996-02-05 1997-10-28 Sankyo Co Ltd 経口投与用５α−リダクターゼ阻害製剤及びその製造方法
JPH1121241A (ja) 1997-07-03 1999-01-26 Otsuka Pharmaceut Co Ltd 固形製剤組成物
US6143323A (en) * 1996-11-15 2000-11-07 Ajinomoto Co., Inc. Tablet composition
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
US6328994B1 (en) * 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US20020155156A1 (en) * 2001-04-18 2002-10-24 Nostrum Pharmaceuticals, Inc. Novel coating for a sustained release pharmaceutical composition
US20030236398A1 (en) * 2002-06-21 2003-12-25 Shingo Niinobe Water-soluble cellulose ether having improved filtering characteristics and selection method
JP2004137272A (ja) 2002-09-26 2004-05-13 Sumitomo Pharmaceut Co Ltd 溶出性の良好なイソキサゾール誘導体経口製剤
WO2004073716A1 (en) * 2003-02-24 2004-09-02 Otsuka Pharmaceutical Co., Ltd. Method for treating severe heart failure and medicament therefor
WO2005007167A1 (ja) 2003-07-17 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. 固形製剤
US20070071811A1 (en) 2005-09-28 2007-03-29 Mali Kadosh Stable combinations of amlodipine besylate and benazepril hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1607087A1 (en) * 2003-03-27 2005-12-21 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2071511A (en) * 1934-10-01 1937-02-23 Reed & Carnrick Enteric coating
JPH04154765A (ja) 1989-10-20 1992-05-27 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
WO1997022340A1 (en) 1995-12-20 1997-06-26 Bristol-Myers Squibb Company Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof
US6036975A (en) 1995-12-20 2000-03-14 A/S Gea Farmaceutisk Fabrik Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof
JPH09278656A (ja) 1996-02-05 1997-10-28 Sankyo Co Ltd 経口投与用５α−リダクターゼ阻害製剤及びその製造方法
US6143323A (en) * 1996-11-15 2000-11-07 Ajinomoto Co., Inc. Tablet composition
JPH1121241A (ja) 1997-07-03 1999-01-26 Otsuka Pharmaceut Co Ltd 固形製剤組成物
US6328994B1 (en) * 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
US20020155156A1 (en) * 2001-04-18 2002-10-24 Nostrum Pharmaceuticals, Inc. Novel coating for a sustained release pharmaceutical composition
US20030236398A1 (en) * 2002-06-21 2003-12-25 Shingo Niinobe Water-soluble cellulose ether having improved filtering characteristics and selection method
JP2004137272A (ja) 2002-09-26 2004-05-13 Sumitomo Pharmaceut Co Ltd 溶出性の良好なイソキサゾール誘導体経口製剤
WO2004073716A1 (en) * 2003-02-24 2004-09-02 Otsuka Pharmaceutical Co., Ltd. Method for treating severe heart failure and medicament therefor
US20050187210A1 (en) 2003-02-24 2005-08-25 Atsushi Ozaki Method for treating severe heart failure and medicament therefor
WO2005007167A1 (ja) 2003-07-17 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. 固形製剤
US20060029663A1 (en) 2003-07-17 2006-02-09 Kyowa Hakko Kogyo Co., Ltd Solid formulation
US20070071811A1 (en) 2005-09-28 2007-03-29 Mali Kadosh Stable combinations of amlodipine besylate and benazepril hydrochloride

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Board Opinion dated Jan. 15, 2014, for CN Patent Application No. 200880021079.9.
Gissinger et al., "A Comparative Evaluation of the Properties of Some Tablet Disintegrants," Drug Development and Industrial Pharmacy, 1980, vol. 6, No. 5, pp. 511-536 (26 pages total).
Nakagawa et al. JP-11021241. "Solid Preparation Composition". Jan. 26, 1997. Machine translation. *
R.C. Rowe et al., "Handbook of Pharmaceutical Excipients," Jan. 2005 (101), pp. 340.
Shin Etsu ("L-HPC: Low-substituted hydroxypropylcellulose." http://www.metolose.jp/en/pharmaceutical/l-hpc.html. 2pgs. Aug. 20, 2019) (Year: 2019). *
Tu Xide, et al., Pharmacy, 3rd edition, pp. 692-693.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022256378A1 (en) 2021-06-02 2022-12-08 Esperion Therapeutics, Inc. Compositions containing and therapies using bempedoic acid and tolvaptan

Also Published As

Publication number Publication date
PL2167046T3 (pl) 2011-05-31
WO2008156217A2 (en) 2008-12-24
WO2008156217A3 (en) 2009-02-26
AR067077A1 (es) 2009-09-30
US20100323006A1 (en) 2010-12-23
HK1201719A1 (en) 2015-09-11
BRPI0813100A2 (pt) 2014-12-23
CY1111939T1 (el) 2015-11-04
KR20100038386A (ko) 2010-04-14
US20230321113A1 (en) 2023-10-12
PT2167046E (pt) 2011-02-10
CN103463095A (zh) 2013-12-25
AU2008264445B2 (en) 2013-06-27
MX2009014193A (es) 2010-01-28
ATE489944T1 (de) 2010-12-15
US20210069207A1 (en) 2021-03-11
EP2167046B1 (en) 2010-12-01
DK2167046T3 (da) 2011-01-31
RU2466717C2 (ru) 2012-11-20
TWI405574B (zh) 2013-08-21
IL202179A0 (en) 2010-06-16
SI2167046T1 (sl) 2011-03-31
TW200911270A (en) 2009-03-16
JP2010530355A (ja) 2010-09-09
CN103989644A (zh) 2014-08-20
MY147599A (en) 2012-12-31
CN101686941A (zh) 2010-03-31
HRP20100676T1 (hr) 2011-01-31
KR101526625B1 (ko) 2015-06-05
CA2689467A1 (en) 2008-12-24
DE602008003816D1 (de) 2011-01-13
AU2008264445A1 (en) 2008-12-24
JP5289338B2 (ja) 2013-09-11
ES2354030T3 (es) 2011-03-09
IL202179A (he) 2012-10-31
RU2010101797A (ru) 2011-07-27
EP2167046A2 (en) 2010-03-31
US20210113582A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
US20230321113A1 (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
EP2586464B1 (en) Tolvaptan solid dispersion and its preparation method
JP2006206612A (ja) 固形製剤用組成物
US11382912B2 (en) Controlled-release preparation
WO2020021110A1 (en) Pharmaceutical composition of ticagrelor
JP2003238393A (ja) 施錠性が改善された錠剤及びその製造方法
US9675549B2 (en) Tablet containing composite with cyclodextrin
JP6321131B2 (ja) アムロジピン含有配合錠の溶出性改善方法
JP2019089758A (ja) セレコキシブ含有錠剤における溶出性の改善方法
JP2006008676A (ja) 固形製剤用組成物
JP2017132724A (ja) アムロジピン含有被覆造粒物を含む配合口腔内崩壊錠
JP2024003789A (ja) 時限放出型顆粒およびその用途
EA047149B1 (ru) Фармацевтическая композиция, содержащая тикагрелор
TWI523842B (zh) 托伐普坦固體分散體及其製備方法
TW202342054A (zh) 經口固形製劑
JP2019116462A (ja) 変色性が改善された、セレコキシブ含有錠剤
WO2013137441A1 (ja) 経口医薬組成物

Legal Events

Date Code Title Description
AS Assignment

Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKAGAWA, SHINSUKE;SUZUKI, KAI;MUKAI, TADASHI;SIGNING DATES FROM 20091104 TO 20091109;REEL/FRAME:023677/0960

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4